Join
Live feed
·
INSIDERFilingvia Quantisnow
Xenon Pharmaceuticals Inc. logo

Director Patou Gary converted options into 2,645 shares, increasing direct ownership by 11% to 26,218 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
XENE· Xenon Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track XENE (Xenon Pharmaceuticals Inc.) and more on Quantisnow.